Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PTC Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $-90.6 Mil. PTC Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $1,799.6 Mil.
Therefore, PTC Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2022 was -0.05.
The historical rank and industry rank for PTC Therapeutics's Equity-to-Asset or its related term are showing as below:
PTCT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.41 Med: 0.4 Max: 0.96
Current: -0.05
During the past 11 years, the highest Equity to Asset Ratio of PTC Therapeutics was 0.96. The lowest was -5.41. And the median was 0.40.
PTCT's Equity-to-Asset is ranked worse than 91.9% of 1555
companies
in the Biotechnology industry
Industry Median: 0.75
vs PTCT: -0.05
PTC Therapeutics Equity-to-Asset Historical Data
The historical data trend for PTC Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Equity-to-Asset
0.40
0.31
0.37
0.22
-
PTC Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Equity-to-Asset
0.14
0.10
0.05
-
-0.05
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Equity-to-Asset Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Equity-to-Asset falls into.
PTC Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PTC Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PTC Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of PTC Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.99(3.14%) Volume: 437,520 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
